ArticleChemMedChem2026
Fragmentation of Vancoresmycin Reveals a Strong Dependence on Global Molecular Architecture for Antibacterial Activity.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vancoresmycin is a structurally complex tetramic-acid-containing natural product with potent activity against Gram-positive bacteria, yet its structure-activity relationships remain poorly defined. In particular, it is unclear whether discrete substructures contribute independently to antibacterial activity or whether biological function depends on the integrity of the full molecular framework. Here, we report the synthesis and biological evaluation of a series of structurally defined fragments derived from vancoresmycin and its aglycon amycomycin, including the tetramic acid core, eastern and western polyketide segments, and the mycosamine residue. Despite preserving key structural motifs, the fragments did not exhibit considerable antibacterial activity. Only the western fragment displayed weak activity accompanied by indications of membrane-associated stress. These results demonstrate that antibacterial activity in vancoresmycin cannot be attributed to isolated substructures but instead depends on the integrated molecular architecture. These results provide a framework for future design strategies that preserve global structural properties rather than focusing on discrete motifs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.